Keeping in line with the findings that EPLIN contributes to maintaining the epithelial cytoskeleton, regulating metastatic progression and cell cytokinesis, there has been strong scientific focus on EPLIN and its implications in multiple types of cancer including oral cancer [1,4], breast cancer [4,44], prostate cancer [2,9], squamous cell carcinoma of head and neck (SCCHN) [9], lung cancer [45], oesophageal cancer [46], ovarian cancer [47], colorectal cancer (CRC) [9,16,18,48,49] and most recently gastric cancer [50]. Here, LIMA1 is linked to breast carcinoma.